Effect of alkyl-lysophospholipids on some aspects of the metabolism of Leishmania donovani

Journal of Parasitology

Volumn 93, Issue 5, 2007, Pages 1202-1207

  Azzouz, S ^a   Maache, M ^a   Sanchez Moreno M ^a   Petavy, A F ^a,b   Osuna, A ^a  

^a Department of Parasitology   (Spain)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; EDELFOSINE; ILMOFOSINE; ISOMERASE; LISOPHOSPHOLIPID; MILTEFOSINE; PHOSPHOLIPASE C; PHOSPHOLIPID; PYRUVIC ACID; SUCCINIC ACID; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

BIOCHEMISTRY; CHEMOTHERAPY; DISEASE TREATMENT; ENZYME ACTIVITY; METABOLISM; NUCLEAR MAGNETIC RESONANCE; PHOSPHOLIPID; PROTOZOAN;

ARTICLE; BACTERIAL STRAIN; BIOCHEMISTRY; CATABOLISM; DRUG EFFICACY; ENZYME INHIBITION; GLUCOSE METABOLISM; LEISHMANIA DONOVANI; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; VISCERAL LEISHMANIASIS;

ANIMALS; CARBOHYDRATE METABOLISM; HUMANS; LEISHMANIA DONOVANI; MAGNETIC RESONANCE SPECTROSCOPY; PARASITIC SENSITIVITY TESTS; PHOSPHOLIPID ETHERS; PHOSPHORYLCHOLINE; PROTOZOAN PROTEINS; SUPEROXIDE DISMUTASE; TYPE C PHOSPHOLIPASES;

LEISHMANIA DONOVANI; PROTOZOA;

EID: 36749065535     PISSN: 00223395     EISSN: None     Source Type: Journal    
DOI: 10.1645/GE-1086R1.1     Document Type: Article

References (49)

1. ACHTERBERG, V., AND G. GERCKEN. 1987. Metabolism of ether lysophospholipids in Leishmania donovani promastigotes. Molecular and Biochemical Parasitology 26: 277-287.
2. ANDREESEN, R., J. OSTERHOLZ, G. A. LUCKENBACH, U. COSTABEL, A. SCHULZ, V. SPETH, P. G. MUNDER, AND G. W. LOHR. 1984. Tumor cytotoxicity of human macrophages after incubation with synthetic analogues of 2-lysophosphatidylcholine. Journal of the National Cancer Institute 72: 53-59.
3. AZZOUZ, S., M. MAACHE, M. F. DOS SANTOS, M. E. SARCIRON, A. F. PETAVY, AND A. OSUNA. 2006. Aspects of the cytological activity of edelfosine, miltefosine, and ilmofosine in Leishmania donovani. Journal of Parasitology 92: 877-883.
4. BERMEYER, H. V. 1988. Methods of enzymatic analysis. Verlag-Chemie/Academic Press, New York, New York, 421 p.
5. BERRIDGE, M. J., AND R. F. IRVINE. 1989. Inositol phosphates and cell signalling. Nature 21: 197-205.
6. BESTEIRO, S., M. BIRAN, N. BITEAU, V. COUSTOU, T. BALTZ, P. CANIONIS, AND F. BRINGAUD. 2002. Succinate secreted by Trypanosoma brucei is produced by a novel and unique glycosomal enzyme, NADH-dependent fumarate reductase. Journal of Biological Chemistry 277: 38001-38012.
7. BRADFORD, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein using the principles of protein-dye binding. Analytical Biochemistry 72: 248-254.
8. 1H] NMR characterization of amastigote-like forms. Molecular and Cellular Biochemistry 42: 89-97.
9. CHARP, P. A., Q. Z. ZHOU, M. G. WOOD, JR., R. L. RAYNOR, F. M. MENGER, AND J. F. KUO. 1988. Synthetic branched-chain analogues of distearoylphosphatidylcholine: Structure-activity relationship in inhibiting and activating protein kinase C. Biochemistry 27: 4607-4612.
10. COOMBS, G. H., J. A. CRAFT, AND D. T. HART. 1982. A comparative study of Leishmania mexicana amastigotes and promastigotes: Enzyme activities and subcellular locations. Molecular and Biochemical Parasitology 51: 199-211.
11. CROFT, S. L., D. SNOWDON, AND V. YARDLEY. 1996. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. Journal of Antimicrobial Chemotherapy 38: 1041-1047.
12. CROSS, G. A., R. A. KLEIN, AND D. J. LINSTEAD. 1975. Utilization of amino acids by Trypanosoma brucei in culture: L-threonine as a precursor for acetate. Parasitology 71: 11-26.
13. FAIRLAMB, A. H., AND F. R. OPPERDOES. 1986. Carbohydrate metabolism in African trypanosomes with special reference to the glycosome. In Carbohydrate metabolism in cultured cells, M. J. Morgan (ed.). Plenum Publishing Corp., New York, New York, p. 183-224.
14. GAJATE, C., AND F. MOLLINEDO. 2002. Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH(3) (edelfosine), a proapoptotic agent in tumor cells. Current Drug Metabolism 3: 491-525.
15. GEILEN, C. C., A. HAASE, T. WIEDER, D. ARNDT, R. ZEISIG, AND W. REUTTER. 1994. Phospholipid analogues: Side chain- and polar head group-dependent effects on phosphatidylcholine biosynthesis. Journal of Lipid Research 35: 625-632.
16. GILROY, F. V., M. R. EDWARDS, R. S. NORTON, AND W. J. O'SULLIVAN. 1988. Metabolic studies of the protozoan parasite, Crithidia lucilae, using proton nuclear magnetic resonance spectroscopy. Molecular and Biochemical Parasitology 31: 107-115.
17. HAMPTON, R. Y., AND O. H. MORAND. 1989. Sphingomyelin synthase and PKC activation. Science 243: 500-507.
18. HANNUN, Y. A., AND L. M. OBEID. 1995. Ceramide: An intracellular signal for apoptosis. Trends in Biochemical Sciences 20: 73-77.
19. HART, D. T., AND F. R. OPPERDOES. 1984. The occurrence of glycosomes (microbodies) in the promastigote stage of four major Leishmania species. Molecular and Biochemical Parasitology 13: 159-172.
20. HEESBEEN, E. C., L. F. VERDONCK, S. W. HERMANS, H. G. VAN HEUGTEN, G. E. STAAL, AND G. RIJKSEN. 1991. Alkyllysophospholipid ET-18-OCH3 acts as an activator of protein kinase C in HL-60 cells. FEBS Letters 290: 231-234.
21. HOFMANN, J., P. M. O'CONNOR, J. JACKMAN, C. SCHUBERT, F. UEBERALL, K. W. KOHN, AND H. GRUNICKE. 1994. The protein kinase C inhibitor ilmofosine (BM 41 440) arrests cells in G2 phase and suppresses CDC2 kinase activation through a mechanism different from that of DNA damaging agents. Biochemical and Biophysical Research Communications 199: 937-943.
22. LIRA, R., L. M. CONTRERAS, R. M. SANTA- RITA, AND J. A. URBINA. 2001. Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole. Journal of Antimicrobial Chemotherapy 47: 537-546.
23. LORENTE, S. O., J. C. F. RODRIGUES, C. J. JIMÉNEZ, M. JOYCE-MENEKSE, C. RODRIGUES, S. L. CROFT, V. YARDLEY, K. DE LUCA-FRADLEY, L. M. RUIZ-PÉREZ, J. URBINA, ET AL. 2004. Novel azasterols as potential agents for treatment of leishmaniasis and trypanosomiasis. Antimicrobial Agents and Chemotherapy 48: 2937-2950.
24. LUX, H., N. HEISE, T. KLENNER, D. HART, AND F. R. OPPERDOES. 2000. Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania. Molecular and Biochemical Parasitology 111: 1-14.
25. MANSON-BAHR, P. E. C. 1982. Apted FIC: Leishmaniasis. In Manson's tropical diseases, B. Tindall (ed.). Manson-Bahr, London, U.K., p. 93-115.
26. MCGREGOR, A. 1998. WHO warns of epidemic leishmania. Lancet 351: 575.
27. MISSET, O., AND F. R. OPPERDOES. 1984. Simultaneous purification of hexokinase, class-I fructose-bisphosphate aldolase, triosephosphate isomerase and phosphoglycerate kinase from Trypanosoma brucei. European Journal of Biochemistry 144: 475-483.
28. _, O. J. BOS, AND F. R. OPPERDOES. 1986. Glycolytic enzymes of Trypanosoma brucei: Simultaneous purification, intraglycosomal concentrations and physical properties. European Journal of Biochemistry 157: 441-453.
29. MUNDER, P. G., AND O. WESTPHAL. 1990. Antitumoral and other biomedical activities of synthetic ether lysophospholipids. Chemical Immunology 49: 206-235.
30. NISHIZUKA, Y. 1992. Intracellular signalling by hydrolysis of phospholipids and activation of protein kinase C. Science 23: 607-614.
31. NJOGU, R. M., C. J. WHITTAKER, AND G. C. HILL. 1980. Evidence for a branched electron transport chain in Trypanosoma brucei. Molecular and Biochemical Parasitology 1: 13-29.
32. NOSEDA, A., P. L. GODWIN, AND E. J. MODEST. 1988. Effects of antineoplastic ether lipids on model and biological membranes. Biochimica et Biophysica Acta 945: 92-100.
33. OPPERDOES, F. R. 1987. Compartmentation of carbohydrate metabolism in trypanosomes. Annual Review of Immunology 41: 127-151.
34. OVERATH, P., J. CZICHOS, AND C. HAAS. 1986. The effect of citrate/cis-aconitate on oxidative metabolism during transformation of Trypanosoma brucei. European Journal of Biochemistry 160: 175-182.
35. PAOLETTI, F., AND A. MOCALI. 1990. Determination of superoxide dismutase activity by purely chemical system based on NAD(P)H oxidation. Methods in Enzymology 186: 209-220.
36. PEARSON, R. D., AND Q. SOUSA. 1985. Leishmania species: Kala-azar, cutaneous and mucocutaneous leishmaniasis. In Principles and practice of infectious diseases, G. L. Mandell, R. G. Douglas, and J. E. Benet (eds.). Wiley, New York, New York, p. 522-531.
37. PRADINAUD, R., I. GIRORDEAU, AND D. SAINTE-MARIF. 1985. Pentamidine excellent drug for the treatment of cutaneous leishmaniasis: Single dose treatment schedule recommended in French Guiana. Anais Brasileira de Dermatologia 60: 385-387.
38. SCHREIBER, B. M., M. D. LAYNE,. AND E. J. MODEST. 1994. Superoxide production by macrophages stimulated in vivo with synthetic ether lipids. Lipids 29: 237-242.
39. SOTO, J., B. A. ARANA, J. TOLEDO, N. RIZZO, J. C. VEGA, A. DIAZ, M. LUZ, P. GUTIERREZ, M. ARBOLEDA, J. D. BERMAN, ET AL. 2004. Miltefosine for new world cutaneous leishmaniasis. Clinical Infectious Diseases 38: 1266-1272.
40. STECK, E. A. 1974. The leishmaniases. In Progress in drug research, E. Jucker (ed.). Birkhauser Verlag, Stuttgart, Germany, p. 289-351.
41. STEIGER, R. F., F. R. OPPERDOES, AND J. BONTEMPS. 1980. Subcellular fractionation of Trypanosoma brucei blood-stream form with special reference to hydrolases. European Journal of Biochemistry 105: 163-175.
42. SUNDAR, S., T. K. JHA, C. P. THAKUR, J. ENGEL, H. SINDERMANN, C. FISCHER, K. JUNGE, A. BRYCESON, AND J. BERMAN. 2002. Oral miltefosine for Indian visceral leishmaniasis. New England Journal of Medicine 347: 1739-1746.
43. URBINA, J. A. 2006. Mechanisms of action of lysophospholipids analogues against trypanosomatids parasites. Transactions of the Royal Society of Tropical medicine and Hygiene 100S: S9-S16.
44. VIEIRA, L. L., N. SACERDOTI-SIERRA, AND C. L. JAFFE. 2002. Effect of pH and temperature on protein kinase release by Leishmania donovani. International Journal for Parasitology 32: 1085-1093.
45. WIEDER, T., C. PERLITZ, M. WIEPRECHT, R. T. HUANG, C. C. GEILEN, AND C. E. ORFANOS. 1995. Two new sphingomyelin analogues inhibit phosphatidylcholine biosynthesis by decreasing membrane-bound CTP: Phosphocholine cytidylyltransferase levels in HaCaT cells. Biochemical Journal 1: 873-879.
46. _, C. E. ORFANOS, AND C. C. GEILEN. 1998. Induction of ceramide-mediated apoptosis by the anticancer phospholipid analog, hexadecylphosphocholine. Journal of Biological Chemistry 273: 1125-1031.
47. _, W. REUTTER, C. E. ORFANOS, AND C. C. GEILEN. 1999. Mechanisms of action of phospholipid analogs as anticancer compounds. Progress in Lipid Research 38: 249-259.
48. _, Z. ZHANG, C. C. GEILEN, C. E. ORFANOS, A. E. GIULIANO, AND M. C. CABOT. 1996. The antitumor phospholipid analog, hexadecylphosphocholine, activates cellular phospholipase D. Cancer Letters 100: 71-79.
49. WRIGHT, M. M., A. G. HOWE, AND V. ZAREMBERG. 2004. Cell membranes and apoptosis: Role of cardiolipin, phosphatidylcholine, and anticancer lipid analogues. Biochemistry and Cell Biology 82: 18-26.